DE60336214D1 - Methoden zur analyse von antikörperdisulfidisomere - Google Patents

Methoden zur analyse von antikörperdisulfidisomere

Info

Publication number
DE60336214D1
DE60336214D1 DE60336214T DE60336214T DE60336214D1 DE 60336214 D1 DE60336214 D1 DE 60336214D1 DE 60336214 T DE60336214 T DE 60336214T DE 60336214 T DE60336214 T DE 60336214T DE 60336214 D1 DE60336214 D1 DE 60336214D1
Authority
DE
Germany
Prior art keywords
antibody
tnfalpha
relates
present
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60336214T
Other languages
German (de)
English (en)
Inventor
Ned M Mozier
Robert L Dufield
Jianming Mo
Gary S Bild
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Application granted granted Critical
Publication of DE60336214D1 publication Critical patent/DE60336214D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
DE60336214T 2002-03-20 2003-03-20 Methoden zur analyse von antikörperdisulfidisomere Expired - Lifetime DE60336214D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36635002P 2002-03-20 2002-03-20
PCT/US2003/008608 WO2003080674A1 (en) 2002-03-20 2003-03-20 Antibody disulfide isomers, use thereof, and methods of analyzing same

Publications (1)

Publication Number Publication Date
DE60336214D1 true DE60336214D1 (de) 2011-04-14

Family

ID=28454787

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60336214T Expired - Lifetime DE60336214D1 (de) 2002-03-20 2003-03-20 Methoden zur analyse von antikörperdisulfidisomere

Country Status (10)

Country Link
US (1) US20060171940A1 (enExample)
EP (1) EP1495056B1 (enExample)
JP (2) JP4441269B2 (enExample)
AT (1) ATE500273T1 (enExample)
AU (1) AU2003225900A1 (enExample)
DE (1) DE60336214D1 (enExample)
DK (1) DK1495056T3 (enExample)
ES (1) ES2358505T3 (enExample)
PT (1) PT1495056E (enExample)
WO (1) WO2003080674A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
EP2004231A4 (en) 2006-04-07 2013-07-10 Nektar Therapeutics CONJUGATES OF ANTI-TNF-ALPHA ANTIBODY
EP2451838A1 (en) * 2009-07-09 2012-05-16 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Stabilized immunoglobulin constant domains
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
CN119861168B (zh) * 2024-12-30 2025-09-23 浙江大学 一种识别β-内酰胺类抗生素中二聚物异构体的智能分析系统及方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849352A (en) * 1984-10-09 1989-07-18 Sullivan John B Antibody purification process
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
JP4418745B2 (ja) * 2002-05-28 2010-02-24 ユセベ ファルマ ソシエテ アノニム 抗体ｐｅｇ位置異性体、それを含む組成物及びその使用

Also Published As

Publication number Publication date
WO2003080674A1 (en) 2003-10-02
AU2003225900A1 (en) 2003-10-08
PT1495056E (pt) 2011-03-29
JP5352761B2 (ja) 2013-11-27
JP2009153528A (ja) 2009-07-16
EP1495056A1 (en) 2005-01-12
JP2006505497A (ja) 2006-02-16
EP1495056A4 (en) 2005-09-28
ATE500273T1 (de) 2011-03-15
EP1495056B1 (en) 2011-03-02
ES2358505T3 (es) 2011-05-11
JP4441269B2 (ja) 2010-03-31
US20060171940A1 (en) 2006-08-03
DK1495056T3 (da) 2011-05-02

Similar Documents

Publication Publication Date Title
EA200201214A1 (ru) Замещенные тиоацетамиды
DE60230029D1 (de) Immunisierungstherapie zur behandlung von atherosklerose
EA201001528A1 (ru) Антитела к склеростину и способы их применения
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NO20014584D0 (no) Proteinisolering og -analyse
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
DE69800716D1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
MXPA02007756A (es) Anticuerpos que aglutinan interleuqina-18 humana y metodos de fabricacion y uso.
BR0308585A (pt) Anticorpos anti-alfavbeta6
EA200601545A1 (ru) АНТИ-Aβ АНТИТЕЛА
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
BR0315161A (pt) Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição
ATE554390T1 (de) Verfahren zur gewinnung von antikörpern
DE60134136D1 (de) Zytokinrezeptoruntereinheit-proteine aus säugetieren, damit zusammenhängende reagenzien und methoden
AR033978A1 (es) Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas
WO2022020234A3 (en) Immunoassay for sars-cov-2 neutralizing antibodies and materials therefor
EA200401628A1 (ru) Ингибиторы пептидной деформилазы
ATE500273T1 (de) Methoden zur analyse von antikörperdisulfidisomere
SE0000675D0 (sv) Monoclonal antibodies
ATE288589T1 (de) Verfahren zur analyse von proteinen
DE50212790D1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
CY1105380T1 (el) Προτιμωμενα τμηματα της νευρικης νηματικης πρωτεϊνης και μεθοδοι χρησης αυτων
DE602004029156D1 (de) Prognose des verlaufs einer krebserkrankung
ATE445842T1 (de) Nachweis spezifischer nitrierter marker